Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has ...
In the first study 1, clinicians in Wuhan, China observed that a subset of infected individuals who tested negative for COVID-19 using qPCR tested positive using ddPCR. The findings suggest that ddPCR ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), and Gencurix, Inc. (KOSDAQ: 229000), announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix’ ...
Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...
“Bio-Rad is proud to announce our first FDA-cleared liquid biopsy test in oncology,” said Annette Tumolo, Bio-Rad EVP and President, Life Science Group. “The QXDx AutoDG ddPCR System and QXDx BCR-ABL ...
HERCULES, Calif., 05/18/2020 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its CFX96 Dx Real-Time ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, and NuProbe USA, a genomics and molecular diagnostics company, recently ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results